KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.
Also called NCT02268994
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 234 participants
- Sponsor
- Registry
-
NCT02268994
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02268994. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2018-02-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
- Condition
- Anemia of Chronic Kidney Disease
- Intervention (Drug)
- ferric citrate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Keryx Biopharmaceuticals
Record details
- Record id
cardio:ct-nct02268994- Content hash
e6ced8f970594d0b24f51325eacc34cc157f9d36059fb04ede98b3fb5cd12688